Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology
April 29, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8
April 24, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., April 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
April 02, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., April 02, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
March 08, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
March 07, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference
March 06, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update
February 28, 2019 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty...
Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
February 27, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
February 26, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
February 14, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...